Published On 2018-10-19 03:50 GMT | Update On 2018-10-19 03:50 GMT
Zurich: The U.S. Food and Drug Administration said on Tuesday it approved Pfizer Inc’s drug for an advanced form of breast cancer tied to an inherited gene mutation.
The drug, talazoparib, belongs to a closely watched class of new medicines called PARP inhibitors, which block enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells.
The PARP market is currently dominated by AstraZeneca’s cancer drug Lynparza.
Talazoparib, a once-daily pill that Pfizer acquired with its $14 billion purchase of Medivation in 2016, is indicated for breast cancer triggered by mutation of BRCA genes, which accounts for 25-30 per cent of hereditary breast cancers and 5-10 per cent of all breast cancers.
The FDA also approved Myriad Genetics’ diagnostic test to identify breast cancer patients who are eligible for Pfizer’s talazoparib.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd